Issue 9, 2020

Advances in living cell-based anticancer therapeutics

Abstract

Nanomedicine has huge potential in cancer therapy due to its advantages of improving the solubility, increasing the bioavailability and reducing the side effects of anticancer drugs. However, the intratumoral accumulation of anticancer nanomedicine is still extremely low owing to multiple physiological barriers to drug delivery; thus, it is inefficient for cancer treatments. Inspired by the communication between natural cells and the body environment, living cell-based anticancer therapeutics have been developed as promising drug carriers or active drugs for cancer therapy. In this review, we will survey recent advances in living cell-based anticancer therapeutics by leveraging their physiological characteristics, from long circulating properties to tumor-homing capacity and anticancer immune responses. In addition, future prospects of this field will be discussed.

Graphical abstract: Advances in living cell-based anticancer therapeutics

Article information

Article type
Review Article
Submitted
07 1 2020
Accepted
17 3 2020
First published
07 4 2020

Biomater. Sci., 2020,8, 2344-2365

Advances in living cell-based anticancer therapeutics

H. Dong, X. Xu, L. Wang and R. Mo, Biomater. Sci., 2020, 8, 2344 DOI: 10.1039/D0BM00036A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements